Keywords: Novartis, R&D pipeline, Oncology, Zometa, Tasigna,

Novartis aims to hold global position in oncology, with new drugs and indications, R&D meeting told

Article | 09 December 2009

Print This

Swiss drug giant Novartis gave an upbeat presentation on its oncology R&D pipeline to investors today, outlining plans ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in